Home » Stocks » ADMP

Adamis Pharmaceuticals Corporation (ADMP)

Stock Price: $0.472 USD 0.000 (0.00%)
Updated December 3, 4:00 PM EST - Market open
Pre-market: $0.480 +0.008 (1.76%) Dec 4, 9:28 AM

ADMP Stock Price Chart

Key Info

Market Cap 44.18M
Revenue (ttm) 18.43M
Net Income (ttm) -34.71M
Shares Out 76.04M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $0.472
Previous Close $0.472
Change ($) 0.000
Change (%) 0.00%
Day's Open -
Day's Range 0.470 - 0.500
Day's Volume 298,495
52-Week Range 0.327 - 1.450

ADMP Stock News

GlobeNewsWire - 2 weeks ago

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13th...

Seeking Alpha - 3 weeks ago

Adamis Pharmaceuticals Corporation's (ADMP) CEO Dennis Carlo on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 weeks ago

Adamis (ADMP) delivered earnings and revenue surprises of -150.00% and -47.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 weeks ago

SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a b...

GlobeNewsWire - 4 weeks ago

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, November 9, ...

Zacks Investment Research - 1 month ago

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

SAN DIEGO, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in v...

GlobeNewsWire - 2 months ago

SAN DIEGO, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in v...

GlobeNewsWire - 3 months ago

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the results of its reconvened 2020 annual meeting of stockholders which was in...

Seeking Alpha - 3 months ago

Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Adamis (ADMP) delivered earnings and revenue surprises of -85.71% and -21.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

SAN DIEGO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2020 and provid...

GlobeNewsWire - 3 months ago

SAN DIEGO, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that in response to Adamis’ Pre-Investigational New Drug (IND) fil...

Zacks Investment Research - 3 months ago

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

GlobeNewsWire - 5 months ago

SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC (“USWM” or “US WorldMeds”) began promoting A...

Benzinga - 5 months ago

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) shares are trading higher on Monday. The company announced a license to commercialize Tempol, a patented investigational drug for the treatment of co...

GlobeNewsWire - 5 months ago

SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today a license  to commercialize Tempol, a novel patented investigation...

Seeking Alpha - 6 months ago

Adamis recently reported their Q1 earnings with a miss on EPS and revenue. The COVID-19 pandemic has had a significant impact on the company's US Compounding sales.

Seeking Alpha - 6 months ago

Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2020 and provided a busi...

GlobeNewsWire - 6 months ago

SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced it is reacquiring from Sandoz Inc. the rights to its SYMJEPI ® (epinephrine) I...

Zacks Investment Research - 7 months ago

Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GlobeNewsWire - 7 months ago

SAN DIEGO, April 23, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced publication in the peer reviewed journal Molecules, “The Effects of Int...

GlobeNewsWire - 7 months ago

SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), ha...

Seeking Alpha - 7 months ago

Adamis Pharmaceuticals: Trying To Find A Course Of Action

GlobeNewsWire - 7 months ago

SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that it has received loan proceeds of $3,191,700 (“PPP Loan”) under the Payc...

GlobeNewsWire - 8 months ago

SAN DIEGO, April 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), ...

GlobeNewsWire - 9 months ago

SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced it has entered into a securities purchase agreement...

Seeking Alpha - 9 months ago

Adamis Pharmaceuticals: Waiting For The Next Move

GlobeNewsWire - 9 months ago

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today provided an update on the ZIMHI™ New Drug Application (NDA) resubmission pro...

GlobeNewsWire - 11 months ago

SAN DIEGO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today provided an update on the ZIMHI™ New Drug Application (NDA) resubmission pro...

GlobeNewsWire - 1 year ago

SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that an article entitled “Comparative Pharmacokinetic Analysis of ...

Seeking Alpha - 1 year ago

Adamis Pharmaceuticals Corp (ADMP) CEO Dennis Carlo on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Adamis: Overdue ZIMHI Decision Puts The Brakes On Stock's Downward Trend

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

GlobeNewsWire - 1 year ago

SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that as of the close of business today, Adamis has not received an...

Seeking Alpha - 1 year ago

Adamis Pharmaceuticals and its investors are preparing for ZIMHI's PDUFA on October 31st. I provide a brief background on ZIMHI and recap its journey thus far.

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the presentation of data pertaining to its investigational high do...

Seeking Alpha - 1 year ago

Adamis recently secured a Australian and New Zealand partnership for SYMJEPI. Although this was a positive move for the company, the market responded negatively with a new 52-week low.

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has entered into an exclusive distribution and commercialization agre...

Seeking Alpha - 1 year ago

Adamis recently updated investors on the progress made in the launch of SYMJEPI and SYMJEPI Jr. Unfortunately, the market wasn't impressed and the stock hit another 52-week low.

GlobeNewsWire - 1 year ago

SAN DIEGO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a progress report and marketing update on the U.S. launch of SYMJEPITM (epinep...

GlobeNewsWire - 1 year ago

SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Howard C. Birndorf and Roshawn Blunt to its Board of Directors.

Seeking Alpha - 1 year ago

Adamis recently reported a mixed Q2 earnings with a beat on EPS and a miss on revenue. I review the earnings report and the company's conference call.

Seeking Alpha - 1 year ago

Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Adamis has settled their patent and trademark legal battles with kaléo Inc. Now, Adamis can focus on finding a commercial partner for their ZIMHI product candidate before the October PDUFA.

Seeking Alpha - 1 year ago

Sandoz recently announced the U.S.retail launch of SYMJEPI in the middle of a Epipen shortage around the country.

Other stocks mentioned: NVS
Seeking Alpha - 1 year ago

Adamis has been a tortuous investment for most shareholders due to a never-ending devaluation of their investment. However, it appears the market has created a deep discount.

Seeking Alpha - 1 year ago

Adamis recently announced their Q1 earnings and reported a slight miss on EPS and revenue. However, it was the company's announcement that they cut Op-Ex in order to prevent an offering.

About ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
CEO
Dennis Carlo
Employees
131
Stock Exchange
NASDAQ
Ticker Symbol
ADMP
Full Company Profile

Financial Performance

In 2019, ADMP's revenue was $22.11 million, an increase of 46.58% compared to the previous year's $15.09 million. Losses were -$29.31 million, -24.87% less than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ADMP stock is "Buy." The 12-month stock price forecast is 1.00, which is an increase of 112.00% from the latest price.

Price Target
$1.00
(112.00% upside)
Analyst Consensus: Buy